This information is intended for use by health professionals

1. Name of the medicinal product

Morphine Sulfate 10mg/5ml Oral Solution

2. Qualitative and quantitative composition

Each 5ml dose contains 10mg of Morphine Sulfate.

Excipient(s) with known effect:

Methyl parahydroxybenzoate (E218) – 9.00mg/5ml

Propyl parahydroxybenzoate (E216) – 1.00mg/5ml

Sucrose – 1500.00mg/5ml

Glucose, liquid – 500.00mg/5ml

For the full list of excipients, see section 6.1

3. Pharmaceutical form

Oral solution.

A clear colourless to pale yellow solution.

4. Clinical particulars
4.1 Therapeutic indications

For the relief of severe pain in adults, adolescents (aged 13-18 years) and children (ages 1-12 years).

4.2 Posology and method of administration


Adults: Recommended dose 10-20 mg (5 - 10ml) every 4 hours.

Maximum daily dose: 120 mg per day

Paediatric population:

Children 13-18 years:

Recommended dose 5-20 mg (2.5 – 10 ml) every 4 hours

Maximum daily dose: 120 mg per day

Children 6-12 years:

Recommended dose 5-10 mg (2.5 – 5 ml) every 4 hours

Maximum daily dose: 60 mg per day

Children 1-5 years:

Recommended dose 5 mg (2.5 ml) every 4 hours

Maximum daily dose: 30 mg per day

Children under 1 year:

Not recommended

Dosage can be increased under medical supervision according to the severity of the pain and the patient's previous history of analgesic requirements.

Special populations:

Reduction in dosage may be appropriate in the elderly and in patients with chronic hepatic disease (for acute hepatic disease see section 4.3), renal impairment, severe hypothyroidism, adrenocortical insufficiency, prostatic hypertrophy, shock or where sedation is undesirable.

Discontinuation of therapy

Prior to starting treatment with opioids, a discussion should be held with patients to put in place a strategy for ending treatment with in order to minimise the risk of addiction and drug withdrawal syndrome (see section 4.4).

Method of Administration

For oral use.

When patients are transferred from other morphine preparations oral preparations dosage titration may be appropriate.

Morphine sulfate is readily absorbed from the gastro-intestinal tract following oral administration. However, when Morphine Sulfate Oral Solution is used in place of parenteral morphine, a 50 % to 100 % increase in dosage is usually required in order to achieve the same level of analgesia.


4.3 Contraindications

Hypersensitivity to the active substance(s) or any of excipients listed in section 6.1

Morphine Sulfate Oral Solution is contraindicated in:

• respiratory depression

• obstructive airways disease

• paralytic ileus (see section 4.4)

• acute hepatic disease

• acute alcoholism

• head injuries (see section 4.4)

• coma (see section 4.4)

• increased intracranial pressure (see section 4.4)

• convulsive disorders

• patients with known morphine sensitivity

• concurrent administration with monoamine oxidase inhibitors or within two weeks of discontinuation of their use (see section 4.5)

• patients with phaeochromocytoma. Morphine and some other opioids can induce the release of endogenous histamine and thereby stimulate catecholamine release

• acute asthma exacerbations (see section 4.4 for information relating to use in controlled asthma)

4.4 Special warnings and precautions for use

Care should be exercised if morphine sulfate is given

• in the first 24 hours post-operatively,

• in hypothyroidism (see section 4.2),

• and where there is reduced respiratory function, such as kyphoscoliosis, emphysema, cor pulmonale and severe obesity.


It has been suggested that opioids can be used with caution in controlled asthma. However, opioids are contraindicated in acute asthma exacerbations (see section 4.3).

Head injury and increased intracranial pressure

Morphine Sulfate Oral Solution is contraindicated in patients with increased intracranial pressure, head injuries and coma (see section 4.3). The capacity of morphine to elevate cerebrospinal fluid pressure may be greatly increased in the presence of already elevated intracranial pressure produced by trauma. Also, morphine may produce confusion, miosis, vomiting and other adverse reactions which may obscure the clinical course of patients with head injury.

Abdominal conditions

Morphine sulfate must not be given if paralytic ileus is likely to occur (see section 4.3), or if the patient has bowel or obstructive biliary disease. Should paralytic ileus be suspected or occurring during these, Morphine Sulfate Oral Solution should be discontinued immediately.

Caution should be exercised where there is an obstructive bowel disorder, biliary colic, operations on the biliary tract, acute pancreatitis or prostatic hyperplasia.

If constipation occurs, this may be treated with the appropriate laxatives.

Care should be exercised in patients with inflammatory bowel disease.

Morphine may obscure the diagnosis or clinical course of patients with acute abdominal conditions and complications following abdominal surgery.

Hypotensive effect

The administration of morphine may result in severe hypotension in individuals whose ability to maintain homeostatic blood pressure has already been compromised by depleted blood volume or the concurrent administration of drugs such as phenothiazine or certain anaesthetics (see section 4.5).

Drug dependence, tolerance and potential for abuse

Morphine sulfate is an opioid agonist and controlled drug.

For all patients, prolonged use of this product may lead to drug dependence (addiction), even at therapeutic doses. The risks are increased in individuals with current or past history of substance misuse disorder (including alcohol misuse) or mental health disorder (e.g. major depression).

Additional support and monitoring may be necessary when prescribing for patients at risk of opioid misuse.

A comprehensive patient history should be taken to document concomitant medications, including over-the-counter medicines and medicines obtained on-line, and past and present medical and psychiatric conditions.

Patients may find that treatment is less effective with chronic use and express a need to increase the dose to obtain the same level of pain control as initially experienced. Patients may also supplement their treatment with additional pain relievers. These could be signs that the patient is developing tolerance. The risks of developing tolerance should be explained to the patient.

Overuse or misuse may result in overdose and/or death. It is important that patients only use medicines that are prescribed for them at the dose they have been prescribed and do not give this medicine to anyone else.

Morphine sulfate may be abused by inhaling or injecting the product. These practices pose a significant risk to the abuser that could result in overdose and death.

Patients should be closely monitored for signs of misuse, abuse, or addiction. The clinical need for analgesic treatment should be reviewed regularly.

Drug withdrawal syndrome

Prior to starting treatment with any opioids, a discussion should be held with patients to put in place a withdrawal strategy for ending treatment with Morphine Sulfate Oral Solution.

Drug withdrawal syndrome may occur upon abrupt cessation of therapy or dose reduction. When a patient no longer requires therapy, it is advisable to taper the dose gradually to minimise symptoms of withdrawal. Tapering from a high dose may take weeks to months.

The opioid drug withdrawal syndrome is characterised by some or all of the following: restlessness, lacrimation, rhinorrhoea, yawning, perspiration, chills, myalgia, mydriasis and palpitations. Other symptoms may also develop including irritability, agitation, anxiety, hyperkinesia, tremor, weakness, insomnia, anorexia, abdominal cramps, nausea, vomiting, diarrhoea, increased blood pressure, increased respiratory rate or heart rate.

If women take this drug during pregnancy, there is a risk that their newborn infants will experience neonatal withdrawal syndrome.


Hyperalgesia may be diagnosed if the patient on long-term opioid therapy presents with increased pain. This might be qualitatively and anatomically distinct from pain related to disease progression or to breakthrough pain resulting from development of opioid tolerance. Pain associated with hyperalgesia tends to be more diffuse than the pre-existing pain and less defined in quality. Symptoms of hyperalgesia may resolve with a reduction of opioid dose


Hypersensitivity and anaphylactic reaction have both occurred with the use of Morphine Sulfate Oral Solution. Care should be taken to elicit any history of allergic reactions to opiates. Morphine Sulfate Oral Solution is contraindicated in patients known to be hypersensitive to morphine sulphate (see section 4.3).

Adrenal insufficiency

Opioid analgesics may cause reversible adrenal insufficiency requiring monitoring and glucocorticoid replacement therapy. Symptoms of adrenal insufficiency may include e.g. nausea, vomiting, loss of appetite, fatigue, weakness, dizziness, or low blood pressure.

Decreased sex hormones and increased prolactin

Long-term use of opioid analgesics may be associated with decreased sex hormone levels and increased prolactin. Symptoms include decreased libido, impotence or amenorrhoea.

Risk in special populations

Morphine is metabolised by the liver and should be used with caution in patients with hepatic disease as oral bioavailability may be increased. It is wise to reduce dosage in chronic hepatic and renal disease, severe hypothyroidism, adrenocortical insufficiency, prostatic hypertrophy or shock (see section 4.2).

The active metabolite Morphine-6-glucuronide may accumulate in patients with renal failure, leading to CNS and respiratory depression.

Acute chest syndrome (ACS) in patients with sickle cell disease (SCD)

Due to a possible association between ACS and morphine use in SCD patients treated with morphine during a vaso-occlusive crisis, close monitoring for ACS symptoms is warranted.

Concomitant use of sedative medicines

Concomitant use of Morphine Sulfate Oral Solution and sedative medicines such as benzodiazepines or related drugs may result in sedation, respiratory depression, coma and death.

Because of these risks, concomitant use of Morphine Sulphate Oral Solution and sedative medicines, should be reserved for patients for whom alternative treatment options are not possible. If a decision is made to prescribe Morphine Sulfate Oral Solution concomitantly with sedative medicines, the lowest effective dose should be used, and the duration of treatment should be as short as possible.

Patients should be monitored closely for signs and symptoms of respiratory depression and sedation. In this respect, it is strongly recommended to inform patients and their caregivers to be aware of these symptoms (see also section 4.5).

Concomitant use of oral P2Y12 inhibitor antiplatelet therapy

Within the first day of concomitant P2Y12 inhibitor and morphine treatment, reduced efficacy of P2Y12 inhibitor treatment has been observed (see section 4.5)

Use with rifampicin

Plasma concentrations of morphine may be reduced by rifampicin. The analgesic effect of morphine should be monitored and doses of morphine adjusted during and after treatment with rifampicin.

Excipient related warnings

This product contains 3 g sucrose in each 10 ml dose. This product also contains 1 g corn syrup, which contains glucose, in each 10 ml dose. This should be taken into account in patients with diabetes mellitus. May be harmful to the teeth. Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrose- isomaltase insufficiency should not take this medicine.

Morphine Sulfate Oral Solution Oral Solution contains the excipients methyl parahydroxybenzoate (E218) and propyl parahydroxybenzoate (E216) which may cause allergic reactions (possibly delayed).

4.5 Interaction with other medicinal products and other forms of interaction

Monoamine oxidase inhibitors

Monoamine oxidase inhibitors are known to interact with narcotic analgesics producing CNS excitation or depression with hyper- or hypotensive crisis, therefore their concomitant use with Morphine Sulfate Oral Solution is contraindicated (see section 4.3).


Interactions have been reported in those taking morphine and gabapentin. Reported interactions suggest an increase in opioid adverse events when co-prescribed, the mechanism of which is not known. Caution should be taken where these medicines are co-prescribed.

In a study involving healthy volunteers (N=12), when a 60 mg controlled-release morphine capsule was administered 2 hours prior to a 600 mg gabapentin capsule, mean gabapentin AUC increased by 44% compared to gabapentin administered without morphine. Therefore, patients should be carefully observed for signs of CNS depression, such as somnolence, and the dose of gabapentin or morphine should be reduced appropriately.


Although there are no pharmacokinetic data available for concomitant use of ritonavir with morphine, ritonavir may increase the activity of glucuronyl transferases. Consequently, co-administration of ritonavir and morphine may result in decreased serum concentrations of morphine with possible loss of analgesic effectiveness.


Rifampicin can reduce the serum concentration of morphine and decrease its analgesic effect, the mechanism of which is not known.


Cimetidine inhibits the metabolism of morphine.

CNS depressants

It should be noted that morphine potentiates the effects of other CNS depressants such as tranquillisers, anaesthetics (see section 4.4), sedatives (e.g. benzodiazepines), antipsychotics, tricyclic antidepressants and alcohol, which might lead to respiratory depression, coma and death. The dose and duration of concomitant use should be limited (see section 4.4).


Morphine may increase plasma concentrations of esmolol.


Opioid analgesics including morphine may antagonise the actions of domperidone and metoclopramide on gastro-intestinal activity.

Oral P2Y12 inhibitors

A delayed and decreased exposure to oral P2Y12 inhibitor antiplatelet therapy has been observed in patients with acute coronary syndrome treated with morphine. This interaction may be related to reduced gastrointestinal motility and apply to other opioids. The clinical relevance is unknown, but data indicate the potential for reduced P2Y12 inhibitor efficacy in patients co-administered morphine and a P2Y12 inhibitor (see section 4.4). In patients with acute coronary syndrome, in whom morphine cannot be withheld and fast P2Y12 inhibition is deemed crucial, the use of a parenteral P2Y12 inhibitor may be considered.


The absorption of mexiletine may be delayed by concurrent use of morphine.

Phenothiazine antiemetics

Phenothiazine antiemetics may be given with morphine. However, hypotensive effects have to be considered (see section 4.4).

4.6 Fertility, pregnancy and lactation


Although morphine sulfate has been in general use for many years, there is inadequate evidence of safety in human pregnancy.

Morphine is known to cross the placenta. Therefore, Morphine Sulfate Oral Solution should not be used in pregnancy, especially the first trimester unless the expected benefit is thought to outweigh any possible risk to the foetus.

Regular use during pregnancy may cause drug dependence in the foetus, leading to withdrawal symptoms in the neonate.

If opioid use is required for a prolonged period in a pregnant woman, advise the patient of the risks of neonatal opioid withdrawal syndrome and ensure that appropriate treatment will be available.

Administration during labour may depress respiration in the neonate and an antidote for the child should be readily available

The risk of gastric stasis and inhalation pneumonia is increased in the mother during labour. Since morphine rapidly crosses the placental barrier it should not be used during the second stage of labour or in premature delivery because of the risk of secondary respiratory depression in the newborn infant

Breast feeding

Although morphine sulfate has been in general use for many years, there is inadequate evidence of safety during lactation.

Administration to nursing women is not recommendedas morphine sulfate may be secreted in breast milk, and may cause respiratory depression in the infant.


Long term use of opioid analgesics can cause hypogonadism and adrenal insufficiency in both men and women. This is thought to be dose related and can lead to amenorrhoea, reduced libido, infertility and erectile dysfunction.

Animal studies have shown that morphine may reduce fertility (see 5.3. preclinical safety data).

4.7 Effects on ability to drive and use machines

Morphine sulfate is likely to impair ability to drive and to use machinery. This effect is even more enhanced when used in combination with alcohol or CNS depressants. Patients should be warned not to drive or operate dangerous machinery after taking Morphine Sulfate Oral Solution.

This medicine can impair cognitive function and can affect a patient's ability to drive safely. This class of medicine is in the list of drugs included in regulations under 5a of the Road Traffic Act 1988. When prescribing this medicine, patients should be told:

• The medicine is likely to affect your ability to drive

• Do not drive until you know how the medicine affects you

• It is an offence to drive while under the influence of this medicine

• However you would not be committing an offence (called 'statutory defence') if:

- The medicine has been prescribed to treat a medical or dental problem and

- You have taken it according to the instructions given by the prescriber and in the information provided with the medicine and

- It was not affecting your ability to drive safely.

4.8 Undesirable effects

In normal doses, the commonest side effects of morphine sulfate are nausea, vomiting, constipation, drowsiness and confusion. If constipation occurs, this may be treated with appropriate laxatives. The effects of morphine have led to its abuse and misuse. Dependence and addiction may develop with regular, inappropriate use.

Data from clinical trials are not available. Therefore it is not possible to provide information on the frequencies of undesirable effects except where stated. A full list of currently known adverse reactions is presented below:

SOC Category

Side effect

Immune system disorders


Anaphylactic reactions (see section 4.4)

Anaphylactoid reactions

Psychiatric disorders

Confusional state


Altered mood


Drug dependence (see section 4.4)

Nervous system disorders



Increased intracranial pressure (see section 4.4)


Hyperalgesia (see section 4.4)

Eye disorders


Ear and labyrinth disorders


Respiratory, thoracic and mediastinal disorders

Respiratory depression (see section 4.4 and section 4.6)

Cardiac disorders




Vascular disorders



Gastrointestinal disorders



Constipation (see section 4.4)

Dry mouth

General disorders and administration site conditions


Drug tolerance (see section 4.4)

Drug withdrawal syndrome* (see section 4.4 and section 4.6)

Hepatobiliary disorders

Biliary colic

Skin and subcutaneous tissue disorders




Musculoskeletal and connective tissue disorders

Muscle rigidity

Renal and urinary disorders


Ureteral spasm


Reproductive system and breast disorders

Decreased libido

Erectile dysfunction

*Frequency uncommon (≥ 1/1,000 to < 1/100)

Reporting of suspected adverse drug reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at or search for MHRA Yellow Card in the Google Play or Apple App Store.

4.9 Overdose

Patients should be informed of the signs and symptoms of overdose and to ensure that family and friends are also aware of these signs and to seek immediate medical help if they occur.


Signs of morphine toxicity and overdosage are likely to consist of pin-point pupils, respiratory depression, and hypotension. Circulatory failure, pneumonia aspiration and deepening coma may occur in more severe cases. Convulsions may occur in infants and children. Death may occur from respiratory failure.


Adults: Administer 0.4-2 mg of naloxone intravenously. Repeat at 2-3 minute intervals as necessary to a maximum of 10 mg, or by 2 mg in 500 ml of normal saline or 5 % dextrose (4 micrograms/ml). Children: 5-10 micrograms per kilogram body weight intravenously. If this does not result in the desired degree of clinical improvement, a subsequent dose of 100 mcg/kg body weight may be administered.

Care should always be taken to ensure that the airway is maintained. Assist respiration if necessary. Maintain fluid and electrolyte levels, Oxygen, i.v. fluids, vasopressors and other supportive measures should be employed as indicated. Peak plasma concentrations of morphine are expected to occur within 15 minutes of oral ingestion. Therefore gastric lavage and activated charcoal are unlikely to be beneficial.

Caution: the duration of the effect of naloxone (2-3 hours) may be shorter than the duration of the effect of the morphine overdose. It is recommended that a patient who has regained consciousness after naloxone treatment should be observed for at least 6 hours after the last dose of naloxone.

5. Pharmacological properties
5.1 Pharmacodynamic properties

Opioid analgesic.

ATC Code: N02AA01

Morphine binds to specific receptors which are located at various levels of the central nervous system and also in various peripheral organs. The pain sensation and the affective reaction to pain is relieved by interaction with the receptors in the central nervous system.

5.2 Pharmacokinetic properties


Morphine sulfate is readily absorbed from the gastrointestinal tract following oral administration. Following oral administration of radiolabelled morphine to humans, peak plasma levels were reached after approximately 15 minutes. Morphine undergoes significant first pass metabolism in the liver resulting in a systemic bioavailability of approximately 25% (range 15-49%).


Morphine is distributed throughout the body but found mainly in the kidneys, liver, lung and spleen with lower concentrations being found in the brain and muscles. Approximately one third of morphine in the plasma is protein bound after a therapeutic dose. Morphine diffuses across the placenta and traces of the drug appear in breast milk.


Metabolism of morphine principally involves conjugation to morphine 3- and 6- glucuronides. Small amounts are also metabolised by N-demethylation and O-methylation. Morphine-6-glucuronide has pharmacological effects indistinguishable from those of morphine. The half-life of morphine is approximately 2 hours. The half-life of morphine-6-glucuronide is somewhat longer.


About 10% of a dose of morphine is excreted through the bowel into the faeces. The remainder is excreted in the urine, mainly in the form of conjugates. Approximately 90 % of a single dose of morphine is excreted in 24 hours. Enterohepatic circulation of morphine and its metabolites can occur, and may result in small quantities of morphine being present in the urine or faeces for several days after the last dose.

5.3 Preclinical safety data

In male rats, reduced fertility and chromosomal damage in gametes have been reported.

6. Pharmaceutical particulars
6.1 List of excipients

Methyl parahydroxybenzoate (E218)

Propyl parahydroxybenzoate (E216)


Glucose, liquid

Sodium hydroxide solution (for pH adjustment)

Hydrochloric acid solution (for pH adjustment)

Purified water

6.2 Incompatibilities

Not applicable.

6.3 Shelf life

2 years

After opening: 3 months

6.4 Special precautions for storage

Store below 25°C.

Store in the original container in order to protect from light.

6.5 Nature and contents of container

The finished product is packed in either 100ml, 250ml, 300ml and 500ml conventional amber soda glass (Type III) bottles fitted with a 28mm white, polypropylene, push and turn caps with expanded polyethylene (EPE) liner.

In addition the product is supplied with a 5ml dispensing oral syringe and bottle adaptor.

Not all pack sizes may be marketed.

6.6 Special precautions for disposal and other handling

No special requirements.

7. Marketing authorisation holder

Wockhardt UK Ltd

Ash Road North



LL13 9UF

8. Marketing authorisation number(s)

PL 29831/0563

9. Date of first authorisation/renewal of the authorisation


10. Date of revision of the text